Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | PPARA | Q07869 | 10/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10875297 | 0.90 | L3MBTL1 (0.41) | L3MBTL1PPARGPPARAPOLBSLC6A4 | |
| SCHEMBL11162895 | 0.88 | ACACB (0.42) | POLB | |
| SCHEMBL22644024 | 0.88 | PPARA (0.43) | L3MBTL1PPARGPPARAPOLBSLC6A4 | |
| SCHEMBL27809243 | 0.88 | L3MBTL1 (0.40) | L3MBTL1PPARGPPARAPOLBSLC6A4 | |
| SCHEMBL10875177 | 0.88 | PPARG (0.43) | L3MBTL1PPARGPPARAPOLBCYP1A2 | |
| SCHEMBL14665065 | 0.85 | LMNA (0.41) | L3MBTL1PPARGPPARAPOLBSLC6A4 | |
| SCHEMBL10266604 | 0.82 | SLC6A4 (0.57) | PPARGPPARASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL13123958 | 0.80 | PPARA (0.41) | L3MBTL1PPARGPPARAPOLBSLC6A4 | |
| SCHEMBL13580504 | 0.80 | IDO1 (0.41) | L3MBTL1TSHR | |
| SCHEMBL9191274 | 0.80 | SIGMAR1 (0.49) | L3MBTL1PPARGPPARAPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9919003-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170189434-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METRO INTERNATIONAL BIOTECH, LLC | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | L3MBTL1 856/4885PPARG 3525/4885PPARA 3397/4885 |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | PNP, RPIA, HPRT1 | L3MBTL1 1645/4885PPARG 2492/4885PPARA 2646/4885 |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | L3MBTL1 1645/4885PPARG 2492/4885PPARA 2646/4885 |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | L3MBTL1 4500/4885PPARG 904/4885PPARA 743/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | L3MBTL1 1645/4885PPARG 2492/4885PPARA 2646/4885 |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | L3MBTL1 4500/4885PPARG 904/4885PPARA 743/4885 |
| US-20170290850-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | L3MBTL1 4500/4885PPARG 904/4885PPARA 743/4885 |
| US-20170189434-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | L3MBTL1 4500/4885PPARG 904/4885PPARA 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.